By Colin Kellaher
BioCryst Pharmaceuticals has won U.S. Food and Drug Administration priority review for an application seeking expanded approval of its Orladeyo hereditary-angioedema drug for children ages 2 through 11.
BioCryst on Wednesday said an FDA green light would make Orladeyo the first targeted oral prophylactic therapy for children under the age of 12 with hereditary angioedema, a genetic disorder characterized by recurrent episodes of severe swelling.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. BioCryst said the agency set a target action date of Sept. 12 for the application.
The FDA approved Orladeyo in December 2020 to prevent hereditary-angioedema attacks in patients 12 and older.
BioCryst, a Durham, NC., biotechnology company, earlier this month raised its 2025 global Orladeyo revenue forecast to $580 million to $600 million from a prior range of $535 million to $550 million.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 14, 2025 07:33 ET (11:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。